🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
530,76 USD
Máx. histórico
558,88
4 días
Split 2:1 del 24/08/2000
Caída desde máximo
-5,03%
Rango 52 semanas
403,16 – 568,67
Variación hoy
-4,05%
Cierre anterior
553,15
Rango de hoy
529,15 – 561,96
Volumen hoy
2.372.462
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 30,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 576,29 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 22 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 29/06/2023 | 349,91 | 352,77 | 347,70 | 348,18 | -0,74% | 1,45% | 1.050.800 |
| 28/06/2023 | 348,00 | 351,94 | 345,03 | 350,78 | +1,05% | 1,99% | 1.045.200 |
| 27/06/2023 | 348,05 | 350,08 | 342,63 | 347,12 | -0,09% | 2,14% | 1.258.100 |
| 26/06/2023 | 351,00 | 351,93 | 341,90 | 347,45 | +0,13% | 2,86% | 1.464.400 |
| 23/06/2023 | 346,77 | 347,88 | 342,45 | 347,00 | -0,33% | 1,57% | 1.370.600 |
| 22/06/2023 | 344,08 | 348,59 | 342,03 | 348,16 | +1,42% | 1,91% | 1.265.600 |
| 21/06/2023 | 343,58 | 345,84 | 341,25 | 343,28 | +0,17% | 1,34% | 1.239.600 |
| 20/06/2023 | 350,39 | 350,39 | 342,30 | 342,69 | -1,49% | 2,31% | 1.352.300 |
| 16/06/2023 | 350,00 | 352,19 | 347,01 | 347,89 | -0,34% | 1,48% | 2.614.500 |
| 15/06/2023 | 344,20 | 349,79 | 341,19 | 349,08 | +2,38% | 2,50% | 1.230.800 |
| 14/06/2023 | 342,63 | 342,63 | 338,20 | 340,96 | -0,33% | 1,29% | 835.900 |
| 13/06/2023 | 340,87 | 344,40 | 339,21 | 342,10 | +0,44% | 1,52% | 986.300 |
| 12/06/2023 | 335,91 | 341,08 | 331,87 | 340,60 | +1,94% | 2,74% | 1.417.100 |
| 09/06/2023 | 333,52 | 335,00 | 328,61 | 334,11 | +0,46% | 1,92% | 1.066.200 |
| 08/06/2023 | 324,00 | 334,08 | 323,02 | 332,58 | +2,44% | 3,41% | 1.446.800 |
| 07/06/2023 | 329,13 | 332,00 | 324,04 | 324,65 | -1,74% | 2,42% | 1.139.600 |
| 06/06/2023 | 337,98 | 337,98 | 328,85 | 330,41 | -1,20% | 2,70% | 1.089.100 |
| 05/06/2023 | 334,00 | 335,24 | 332,00 | 334,42 | +0,19% | 0,97% | 1.044.500 |
| 02/06/2023 | 323,00 | 334,53 | 322,25 | 333,78 | +3,14% | 3,80% | 1.572.700 |
| 01/06/2023 | 324,47 | 324,58 | 320,01 | 323,62 | +0,02% | 1,41% | 1.342.900 |
| 31/05/2023 | 327,13 | 328,65 | 321,70 | 323,57 | -0,53% | 2,12% | 5.592.300 |
| 30/05/2023 | 329,82 | 330,07 | 321,62 | 325,30 | -1,42% | 2,56% | 1.888.200 |
| 26/05/2023 | 328,99 | 331,78 | 325,82 | 329,99 | -0,79% | 1,81% | 1.850.500 |
| 25/05/2023 | 330,92 | 333,99 | 327,59 | 332,63 | -0,37% | 1,93% | 1.368.300 |
| 24/05/2023 | 335,77 | 336,57 | 331,05 | 333,85 | +0,10% | 1,64% | 1.154.100 |
| 23/05/2023 | 340,50 | 340,50 | 332,08 | 333,51 | -1,90% | 2,47% | 1.381.500 |
| 22/05/2023 | 344,06 | 346,00 | 337,95 | 339,97 | -0,51% | 2,34% | 961.700 |
| 19/05/2023 | 341,37 | 345,64 | 338,09 | 341,70 | +0,66% | 2,21% | 942.700 |
| 18/05/2023 | 341,10 | 341,10 | 336,35 | 339,46 | -0,51% | 1,39% | 1.139.300 |
| 17/05/2023 | 343,90 | 345,46 | 334,27 | 341,20 | -1,14% | 3,25% | 1.073.800 |